Appendix 4E

Preliminary final report

1. Details of reporting period

Name of entity	Cynata Therapeutics Limited (the Company)
ABN	98 104 037 372
Reporting Period	**Year ended 30 June 2022**
Previous Corresponding Period	Year ended 30 June 2021
Presentation Currency	Australian Dollars ($)

2. Results for announcement to the market

Key information	12 months ended 30 June 2022 $	12 months ended 30 June 2021 $	Increase/ (decrease) %	Amount change $
Revenues from ordinary activities	7,835,174	1,688,351	364.07%	6,146,823
Loss from ordinary activities after tax attributable to members	5,445,172	7,689,683	(29.19%)	(2,244,511)
Net loss for the period attributable to members	5,445,172	7,689,683	(29.19%)	(2,244,511)
Net tangible asset/(deficiency) per share	0.150	0.179		

3. Consolidated statement of profit or loss and other comprehensive income

Refer to attached consolidated financial statements.

4. Consolidated statement of financial position

Refer to attached consolidated financial statements.

5. Consolidated statement of cash flows

Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

Refer to attached consolidated financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

Not applicable.

9. Details of entities over which control has been gained or lost during the period

Not applicable.

10. Details of associate and joint venture entities

Not applicable.

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached consolidated financial statements.

12. Foreign entities

Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

Cynata Therapeutics Limited ("Cynata" or the "Company") and its controlled entities ("the Group") incurred a net loss from operations for the financial year ended 30 June 2022 of $5,445,172 (2021: $7,689,683). At 30 June 2022, the Group had a cash balance of $23,798,046 (2021: $26,716,670) and net assets of $23,960,085 (2021: $28,373,153). The net cash outflow from operating activities for the financial year was $3,298,331 (2021: $5,163,109). During the financial year ended 30 June 2022, the Company received an R&D refund of $832,677 and also received US$5 million from FUJIFILM Corporation under a Strategic Partnership Agreement. During the reporting period, Cynata actively recruited and treated patients in three clinical trials: (1) the Phase 3 SCUlpTOR osteoarthritis clinical trial, (2) the MEND respiratory distress clinical trial and, (3) the Diabetic Foot Ulcers (DFU) clinical trial. The Company also received clearance from the US Food and Drug Administration (FDA) for Cynata's Investigational New Drug (IND) application for a proposed Phase 2 trial in acute graft-versus-host disease (aGvHD). During the financial year, Cynata signed a Strategic Partnership Agreement (SPA) and a Manufacturing Services Agreement with FUJIFILM Corporation and with FUJIFILM Cellular Dynamics, Inc., respectively, for FUJIFILM to manufacture Cymerus™ MSCs for clinical and commercial purposes. In addition, Cynata regained development and commercialisation rights to CYP-001 for graft-versus-host disease (GvHD) as part of the SPA and received a payment of US$5m as part of the SPA. The Company strengthened its intellectual property portfolio, with patents encompassing the Company's unique Cymerus MSC technology being granted in the US, Canada, Russia, China and Japan, which are core markets for the development of cutting-edge regenerative medicine technologies. Cynata reported compelling data from preclinical studies in models of idiopathic pulmonary fibrosis (IPF) and heart attack, with a paper describing the latter published in leading journal, Cytotherapy. Following a review after the completion of FY21-22 and in face of ongoing recruitment challenges, enrolment to the MEND trial was concluded as announced to the market on 12 August 2022. Cynata's core focus for the outlook period is to complete recruitment in its active clinical trials, negotiate with study centres the logistic aspects of the proposed Phase 2 clinical trial in aGvHD, and to continue to engage in commercial discussions with multiple potential partners. Cynata's pipeline is robust and diverse, with positive preclinical data demonstrated in a host of relevant disease models including in IPF, renal transplantation and myocardial infarction (heart attacks). The versatility of MSCs make the Company's Cymerus platform a powerful and valuable clinical asset and Cynata's history of positive preclinical and clinical results are a promising indication that MSCs can be leveraged across a range of target indications.

For more information, refer to the attached consolidated financial statements.

14. Audit

This report is based on accounts which have been audited and the audit report is included in the attached consolidated financial statements.

Dr. Ross Macdonald
Managing Director/Chief Executive Officer

Authorised for release by the Board

24 August 2022